Comparison of Treatment Duration (12 or 24 hours) for Patients with Postpartum Pre-Eclampsia: a Randomized Clinical Study
- Conditions
- Prenatal CareMidwiferyRandomized Controlled TrialC12.050.703.395.249
- Registration Number
- RBR-83fs5dr
- Lead Sponsor
- niversidade Estadual de Campinas
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Pregnant patients, diagnosed with pre-eclampsia, with indication for the use of magnesium sulfate due to maternal cause, as assessed by the care team; start using magnesium sulfate before delivery, with a schedule for maintaining the medication after delivery
Patient unable to understand the informed consent form, due to cognitive incapacity, definitive or temporary, as a result of pre-eclampsia itself (suspected bleeding in the central nervous system) or due to a cause prior to pregnancy. Patients unable to read the informed consent form (because they are intubated or have clinical or imaging evidence of neurological involvement) will not be invited to participate in this study, as they are considered to be in a vulnerable situation that prevents their participation in this protocol; gestational age is less than 24 weeks;
diagnosis of fetal death before delivery (i.e., ultrasound diagnosis of absence of fetal heartbeat upon admission for delivery); presence of multiple pregnancy (more than one fetus); patient with antenatal diagnosis of fetal malformation incompatible with extrauterine life; indication for the use of magnesium sulfate was made exclusively for fetal neuroprotection due to the risk of premature birth, without any maternal clinical indication that would justify its use; magnesium sulfate treatment was suspended before delivery
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method